NCT01274975

Autologous Adipose Derived MSCs Transplantation in Patient With Spinal Cord Injury.

Safety of Autologous Adipose Derived Mesenchymal Stem Cells in Patients With Spinal Cord Injury

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: R-Bio · Industry
• Sex: Male
• Age: 19 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

This study is designed to assess the safety of intravenous autologous adipose derived mesenchymal stem cells transplant in spinal cord injury patients.

Detailed description

Adipose derived mesenchymal stem cells (AdMSCs) represent an attractive and ethical cell source for stem cell therapy. With the recent demonstration of MSC homing properties, intravenous aplications of MSCs to cell-damaged diseases have increased. In a human clinical trial, eight male patients who had suffered a spinal cord injury were intravenously administered autologous hAdMSCs (4×10e8 cells) one time.

Conditions

• Spinal Cord Injury

Interventions

Type	Name	Description
OTHER	Autologous Adipose Derived Mesenchymal Stem Cells	Intravenous infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4 x 10e8 cells

Timeline

• Start date: 2009-07-01
• Primary completion: 2009-11-01
• Completion: 2010-02-01
• First posted: 2011-01-12
• Last updated: 2014-03-26